Barry, OppHub America Desk · · Source: yahoo-tickers-rotation
Regeneron Reports Q3 Revenue and Dupixent Profit Growth
Drug pricing & pharma: Pricing rules, -1, and actions hit large-cap pharma and PBMs/insurers.
Based on reporting from yahoo-tickers-rotation.
Regeneron Pharmaceuticals reported $4.3 billion in revenue, up 17% year-over-year, alongside a 38% increase in global Dupixent sales to $6 billion. While older Eylea formulations faced declines, robust collaboration profits underscore the company's valuation pivot.
Market context for this story
As of: WeekendLoading quotes…
Informational only — not investment advice. Full markets →
$REGNRegeneron Pharmaceuticals
TradingView
Live chart & market data via TradingView · OppHub classroom · Delayed or exchange real-time per TradingView data agreements · Not investment advice
Educational TradingView chart — search any symbol in the widget. Confirm on /markets/REGN. Not investment advice.
Related markets
Shares a vertical MP4 loop to your phone's camera roll or app share sheet (Instagram, TikTok, Facebook Reels).
### Session Tape — $REGN+WL -0.70%, SNY +0.79%
## Catalyst Analysis: Dupixent Profit Share Outpaces Eylea Headwinds
Regeneron Pharmaceuticals ($REGN+WL -0.70%) delivered $4.3 billion in revenue for the period, marking a 17% increase year-over-year. The core driver of expansion was its collaboration with Sanofi (SNY +0.79%), where revenue grew 51% year-over-year to $2.2 billion. Global sales of Dupixent reached $6 billion, representing a 38% year-over-year gain. Non-GAAP net income per share rose 11% year-over-year to $14.29.
Simultaneously, legacy products faced contraction. Sales of the original version of Eylea dropped by 45% year-over-year to $412 million. Although the newer high-dose Eylea formulation generated U.S. revenue of $596 million—up 52% compared to the year-ago period—combined revenue for both formulations declined 12% year-over-year to approximately $1 billion due to biosimilar competition.
Read the full story
Original reporting and related coverage — attribution links only, not paid recommendations.
Trade this story
Robinhood
Webull
Tradier
IBKR
Chart this story
TradingView
Broker and exchange buttons use invite / refer-a-friend links (rewards may be capped). Charting links (TradingView) are partner offers that may pay OppHub America a commission at no extra cost to you.
OppSHOP
Full OppSHOP →As an Amazon Associate, OppHub America earns from qualifying purchases. Shopping here helps keep the site free — at no extra cost to you. Disclosure
OppSHOP
Related to this story
Drug pricing & pharma: Pricing rules, -1, and actions hit large-cap phar
Shop related →
Investing books
Read the classics
Shop this pick →
Personal finance books
Run the household books
Shop this pick →
Trading notebooks
Write the thesis first
Shop this pick →
Monitor for charts
See every pane
Shop this pick →
Story playbook
A pre-built map of what to watch — stocks, ETFs, and educational next steps. Not personalized advice.
Snapshot date: October 17, 2026 at 4:25 PM ET
This playbook was built when the story published and is not live-updated. Prices, news, and risk can change after this date — treat it as a starting map, not a current trade ticket.
Story → money map
Biotech and pharma revenue growth
Regeneron made more money this quarter because its top-selling allergy and eczema drug, Dupixent, is doing extremely well. However, investors are watching out because some of their older eye medicines are selling less due to new competition.
What changed
Regeneron posted $4.3 billion in quarterly revenue, fueled by a 38% jump in global Dupixent sales that offset a decline in legacy Eylea treatments.
Who wins / who loses
Biotech partners and companies with high-growth blockbuster drugs benefit, while traditional drug makers relying on older products face headwinds.
Time horizon
Think in terms of the next few months.
Confidence & best fit
medium confidence · Long-term investor
Safer theme exposure (ETFs)
Baskets that own the theme without betting on one company.
Single stocks (higher risk)
Primary = closest to the story · Peers = same industry · Second-order = knock-on effects · Avoid = looks related but may be a trap
Primary
- $REGNWatch — track, don’t rush
Regeneron's main drug is selling very well, but older drugs are losing sales to cheaper competitors.
View $REGN chart → · End-of-day delayed data
Peer
- $SNYWatch — track, don’t rush
Sanofi shares the profits on the fast-growing Dupixent drug, helping their bottom line.
View $SNY chart → · End-of-day delayed data
Options (education only)
No strikes or expiries — a framework for how traders might express the view. Options can expire worthless.
Beginners should skip options here and stick to regular stock shares if interested.
See options-friendly brokers →Income / OppHub America angle
Not a trade tip — ways to use the insight outside the market.
- Monitor broader regulatory updates regarding drug pricing negotiations and PBM policies.
What would break this thesis
- Accelerating declines in high-dose Eylea adoption or unexpected regulatory hurdles for the drug portfolio.
What to do next on OppHub America
Saved playbooks stay on this device for now.
Important
Not financial advice. OppHub America playbooks are educational market maps only — not recommendations to buy, sell, or hold any security. Markets move fast; information can be wrong or outdated. Trade and invest at your own risk. Do your own research or consult a licensed advisor.
Based on reporting from yahoo-tickers-rotation.
Informational and educational only — not investment, financial, or legal advice. Disclosure
Shares a vertical MP4 loop to your phone's camera roll or app share sheet (Instagram, TikTok, Facebook Reels).